Lung Cancer ESMO 2025 Highlights: MDT-BRIDGE, FLAURA2, SOHO-01, Beamion LUNG-1
Update: 2025-11-06
Description
Welcome to another episode of the Oncology Brothers podcast! In this episode, we are joined by Dr. Rami Manochakian from the Mayo Clinic to discuss the latest practice-changing studies presented at ESMO 2025, focusing on lung cancer.
Episode Highlights:
- MDT-BRIDGE: Trial for resectable and borderline resectable non-small cell lung cancer (NSCLC) stressing the importance of a multidisciplinary approach.
- FLAURA2 Update: showcasing the overall survival benefits of osimertinib combined with chemotherapy for EGFR-positive NSCLC.
- SOHO-01 & Beamion LUNG-1: emerging HER2-positive NSCLC treatments, Zongertinib and Sevabertinib.
- Discussion on the significance of NGS testing in identifying mutations and tailoring treatment options for patients.
Join us as we explore these important studies and their implications for improving patient outcomes in lung cancer care.
Follow us on social media:
- X/Twitter: https://twitter.com/oncbrothers
- Instagram: https://www.instagram.com/oncbrothers
- Website: https://oncbrothers.com/
Don't forget to subscribe for more updates on practice-changing research and major conference highlights!
#ESMO2025 #LungCancer #NSCLC #MDT #Zongertinib #Sevabertinib #Osimertinib #OncologyBrothers
Comments
In Channel
Download from Google Play
Download from App Store
United States00:00
00:00
x
